Should You Buy Aurinia Pharmaceuticals Inc (AUPH) Today? Analysis, Price Targets, and 2026 Outlook.
No data
No data
Growth
Profitability
Efficiency
Wall Street analysts forecast AUPH stock price to rise
6 Analyst Rating
Wall Street analysts forecast AUPH stock price to rise
3 Buy
3 Hold
0 Sell
Moderate Buy
Current: 15.490
Low
13
Averages
16.5
High
21
Current: 15.490
Low
13
Averages
16.5
High
21
Leerink
Outperform -> Market Perform
downgrade
$16
AI Analysis
2025-12-03
Reason
Leerink
Price Target
$16
AI Analysis
2025-12-03
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded Aurinia Pharmaceuticals to Market Perform from Outperform with a $16 price target.
Leerink
Outperform
to
Market Perform
downgrade
$15 -> $16
2025-12-03
Reason
Leerink
Price Target
$15 -> $16
2025-12-03
downgrade
Outperform
to
Market Perform
Reason
Leerink downgraded Aurinia Pharmaceuticals to Market Perform from Outperform with a price target of $16, up from $15. While Aurinia has done well with the commercialization of Lupkynis in lupus nephritis, the product is unlikely to be as big as the firm originally thought and there is some uncertainty regarding the tail of this asset, the analyst tells investors in a research note. Additionally, while Leerink views the aritinercept data favorably, it is coming from behind in a crowded development landscape, and the firm lacks visibility into its differentiation and competitive moat.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AUPH
